[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"leukemialymphoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:leukemialymphoma":38},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":19,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":5},"100363604",false,"NCT04014374","Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab","Inclusion Criteria:\n\n* Patients registered to the Center for International Blood and Marrow Transplant Research (CIBMTR)\n* Adults ≥18 years of age with either CTCL or ATLL;\n* AlloHCT performed from January 2012 onward.\n\nExclusion Criteria:\n\n• Patients without consent for research.","ALL","18 Years",{"count":17,"type":18},150,"ESTIMATED","2 Years","OBSERVATIONAL","This is a non-interventional cohort study evaluating non-relapse mortality and toxicities in patients with CTCL or ATLL treated with mogamulizumab pre- or post- alloHCT for patients transplanted beginning January 1, 2012 until accrual is complete.",[23,24,25],"Leukemia\u002FLymphoma","Cutaneous T Cell Lymphoma","ATLL","RECRUITING","2024-07-23",{"date":29,"type":30},"2024-07-24","ACTUAL",{"date":32,"type":30},"2019-09-10",{"date":34,"type":18},"2030-02",{"name":36,"class":37},"Kyowa Kirin, Inc.","INDUSTRY",""]